Nordic Nanovector ASA: Notice of Annual General Meeting 2016
Oslo, Norway, 28 April 2016
Notice of Nordic Nanovector ASA's (the "Company") (OSE: NANO) Annual General Meeting 2016 has been sent to the Company's shareholders today and can be found enclosed in English and in Norwegian. The Annual General Meeting will be held at Thon Hotel Vika Atrium at Munkedamsveien 45 in Oslo, Norway on 19 May 2016 at 10:00 CEST. Shareholders wishing to attend the Annual General Meeting, in person or by proxy, are requested to complete one of the enclosed attendance forms. The attendance form must be received by the Company's registrar Nordea Bank Norge ASA, Issuer Services to the following address: Postboks 1166 Sentrum, 0107 Oslo or to e-mail; nis@nordea.com at the latest by 15 May 2016 at 16:00 CEST.
The notice of the Annual General Meeting and supporting documents, including the Annual Report for 2015, corporate governance statement and corporate social responsibility statement are available at www.nordicnanovector.com. The proposal from the Nomination Committee will be made available on www.nordicnanovector.com prior to the Annual General Meeting. The Company will publish a new press release when the proposal from the Nomination Committee is available.
For further information, please contact:
Tone Kvåle, Chief Financial Officer
Phone: +47 91 51 95 76
E-mail: ir@nordicnanovector.com
About Nordic Nanovector:
Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company's lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionclide-Conjugates (ARC) designed to improve upon a complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over USD 12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low intensity radionclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulator submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation to Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications. Further information about the Company can be found at www.nordicnanovector.com
This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Tags: